黄芪复方制剂对重症肌无力患者外周血Th1、Th2及Tc1、Tc2细胞亚群的影响

 目的 探讨黄芪复方制剂对重症肌无力(myasthenia gravis,MG)患者的细胞免疫调节机制.方法 将60例随机分为2组,每组30例.治疗组服用中药黄芪复方制剂;对照组服用泼尼松片,疗程12周.应用流式细胞仪检测重症肌无力患者治疗前后外周血Th1、Tc1、Th2、Tc2细胞的变化情况.结果 与健康组比较,MG组外周血中Thl、Th2、Tcl和Tc2细胞百分数明显增高,差异有统计学意义(P＜0.01),Thl/Th2、Tcl/Tc2比值同健康组相比差异有统计学意义(P＜0.05).治疗后,治疗组Th1型、Tc1型细胞明显减少(P＜0.01),与对照组治疗后比较差异有统计学意义(P＜0.05).结论 黄芪复方制剂通过抑制MG患者Th1型细胞和Tc1型细胞的分化,减少Thl/ Tc1型细胞因子如IFN-γ的分泌而起到抗炎和改变病程的作用.

Effect of compound Astragalus membranaceus on Th1,Th2 ,Tc1 and Tc2 subsets in peripheral blood of patients with myasthenia gravis

Objectives To investigate the effect of compound Astragalus membranaceus on immunoregulatory mechanisms of T cell -mediation in patients with myasthenia gravis （MG）. Methods Sixty MG patients were divided into two equal groups randomly, half of whom were given compound Astragalus membranaceus as the treatment group, and the other half was given prednisone tablets and as control. The duration of treatment for both groups was 12 weeks. Distributional changes of the subsets Th1 ,Tc1 ,Th2, and Tc2 of lymphocytes in patients were examined by flow cytometry. Results The Th1,Th2,Tc1 and Tc2 cell percentage in these two groups was significantly higher than that in normal group （P 〈0.01 ） ; Th1/Th2 and Tc1/Tc2 were significantly different from those in normal group （ P 〈 0.05 ）. After treatment, the Th1 and Tc1 cell percentage in the treatment group decreased significantly （ P 〈 0.01 ）, much unlike control group （ P 〈 0.05 ）. Conclusions The effect of the compound Astragalus membranaceus might be related to the prevention of Th1 and Tc1 differentiation and the decrease of Th1 and Tc1 cytokines, such as IFN - γ.